Viking Therapeutics, Inc. (VKTX)
33.50
-0.17
(-0.50%)
USD |
NASDAQ |
Sep 02, 16:00
33.40
-0.10
(-0.30%)
After-Hours: 20:00
Viking Therapeutics Net Income (TTM) : -534.80M for June 30, 2026
Net Income (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -534.80M |
| March 31, 2026 | -472.34M |
| December 31, 2025 | -359.64M |
| September 30, 2025 | -237.39M |
| June 30, 2025 | -171.55M |
| March 31, 2025 | -128.24M |
| December 31, 2024 | -109.96M |
| September 30, 2024 | -99.15M |
| June 30, 2024 | -96.74M |
| March 31, 2024 | -93.72M |
| December 31, 2023 | -85.90M |
| September 30, 2023 | -80.85M |
| June 30, 2023 | -74.09M |
| March 31, 2023 | -72.30M |
| December 31, 2022 | -68.87M |
| September 30, 2022 | -61.66M |
| June 30, 2022 | -59.13M |
| March 31, 2022 | -57.08M |
| December 31, 2021 | -54.99M |
| September 30, 2021 | -53.58M |
| June 30, 2021 | -49.63M |
| March 31, 2021 | -43.82M |
| December 31, 2020 | -39.50M |
| September 30, 2020 | -36.00M |
| Date | Value |
|---|---|
| June 30, 2020 | -32.44M |
| March 31, 2020 | -30.54M |
| December 31, 2019 | -25.78M |
| September 30, 2019 | -23.57M |
| June 30, 2019 | -24.44M |
| March 31, 2019 | -23.44M |
| December 31, 2018 | -22.06M |
| September 30, 2018 | -20.91M |
| June 30, 2018 | -20.41M |
| March 31, 2018 | -18.91M |
| December 31, 2017 | -20.58M |
| September 30, 2017 | -20.14M |
| June 30, 2017 | -17.85M |
| March 31, 2017 | -16.37M |
| December 31, 2016 | -14.73M |
| September 30, 2016 | -16.18M |
| June 30, 2016 | -17.11M |
| March 31, 2016 | -21.28M |
| December 31, 2015 | -23.40M |
| September 30, 2015 | -41.10M |
| June 30, 2015 | -36.51M |
| March 31, 2015 | -28.67M |
| June 30, 2014 | -22.96M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (TTM) Benchmarks
| Vertex Pharmaceuticals, Inc. | 4.405B |
| Eli Lilly & Co. | 26.71B |
| Regeneron Pharmaceuticals, Inc. | 4.329B |
| Skye Bioscience, Inc. | -50.49M |
| Eledon Pharmaceuticals, Inc. | -98.56M |